AU Patent

AU2007296745B2 — Quinazoline based EGFR inhibitors

Assigned to Curis Inc · Expires 2011-12-01 · 14y expired

What this patent protects

The present invention relates to quinazoline containing zinc-binding moiety based derivatives that have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and di…

USPTO Abstract

The present invention relates to quinazoline containing zinc-binding moiety based derivatives that have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer.

Drugs covered by this patent

Patent Metadata

Patent number
AU2007296745B2
Jurisdiction
AU
Classification
—
Expires
2011-12-01
Drug substance claim
No
Drug product claim
No
Assignee
Curis Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.